Trial Profile
Safety and pharmacokinetics of ODM-207 in patients with selected advanced solid tumours: an open-label, non-randomised, uncontrolled, multicentre, first-in-human study with cohort expansion
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs ODM 207 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms BETIDES
- Sponsors Orion Pharma
- 29 Sep 2020 Results published in the British Journal of Cancer
- 14 Oct 2019 Status changed from active, no longer recruiting to completed.
- 07 Jun 2019 This trial has been completed in Finland and spain, according to European Clinical Trials Database record.